Actavis mulls Biopartners' stake to enter biogenerics
This article was originally published in Scrip
Executive Summary
Actavis of Iceland is planning to acquire the 51% stake in Biopartners, the Swiss biogenerics company, currently owned by Poland's largest biotech company, Bioton. Financial terms of the deal have yet to be agreed and will take into account the $78 million that Bioton paid for Biopartners in 2007, the cost of goods associated with the portfolio as well as its commercialisation prospects.